Abstract
Background The economic and reproductive medicine response to the COVID-19 pandemic in the United States has reduced the affordability and accessibility of fertility care. We sought to determine the impact of the 2008 financial recession and the COVID-19 recession on fertility treatments and cumulative live-births.
Methods We examined annual US natality, CDC IVF cycle activity and live birth data from 1999 to 2018 encompassing 3,286,349 treatment cycles, to estimate the age-stratified reduction in IVF cycles undertaken after the 2008 financial recession, with forward quantitative modelling of IVF cycle activity and cumulative live-births for 2020 to 2023.
Results The financial recession of 2008 caused a four-year plateau in fertility treatments with a predicted 53,026 (95% CI 49,581 to 56,471) fewer IVF cycles and 16,872 (95% CI 16,713 to 17,031) fewer live births. A similar scale of economic recession would cause 67,386 (95% CI: 61,686 to 73,086) fewer IVF cycles between 2020 and 2023, with women younger than 35 years overall undertaking 22,504 (95% CI 14,320 to 30,690) fewer cycles, as compared to 4,445 (95% CI 3,144 to 5749) fewer cycles in women over the age of 40 years. This equates to overall 25,143 (95% CI: 22,408 to 27,877) fewer predicted live-births from IVF, of which only 490 (95% CI 381 to 601) are anticipated to occur in women over the age of 40 years.
Conclusions The COVID-19 recession could have a profound impact on US IVF live-birth rates in young women, further aggravating pre-existing declines in total fertility rates.
Trial registration number not applicable
Competing Interest Statement
No competing interests: "No funding bodies had any role in the study design data collection and analysis decision to publish or preparation of the manuscript; SMN has participated in Advisory Boards and received speakers fees from Beckman Coulter; Ferring; Finox; Merck; MSD and Roche Diagnostics; DAL has received grant funding for other studies not related to this one from government charity and industry funders including Roche Diagnostics and Medtronic; DAL is a member of the Editorial Board for BMC Medicine; PSG and ADACS have no conflict of interest; FIS receive the speakers fees from Ferring."
Clinical Trial
Using available statistical data. The Fertility Clinic Success Rate and Certification Act of 1992 requires that all assisted reproductive technology (ART) cycles performed in the United States are reported to the Centers for Disease Control and Prevention (CDC). Fertility clinics submit data to the CDC through the National ART Surveillance System (NASS) reporting system or an approved alternative compliant with federal reporting requirements.
Funding Statement
This work was supported by the National Institute for Health Research Biomedical Centre at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol (DAL, and SMN), a European Research Council grant (DevelopObese; 669545 to DAL), a British Heart Foundation Grant (AA/18/7/34219 to DAL) and a National Institute for Health Research Senior Investigator award (NF-0616-10102 to DAL). DAL work in a Unit that receives support from the University of Bristol and the MRC (MC_UU_00011/6). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care, or any other funders mentioned here.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Glasgow
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* joint senior authors
Data Availability
"Data sources; The Fertility Clinic Success Rate and Certification Act of 1992 requires that all assisted reproductive technology (ART) cycles performed in the United States are reported to the Centers for Disease Control and Prevention (CDC); Fertility clinics submit data to the CDC through the National ART Surveillance System (NASS) reporting system or an approved alternative compliant with federal reporting requirements; The CDC conducts data validation through yearly audits and site visits; The CDC has published Assisted Reproductive Technology Fertility Clinic Success Rates Reports detailing activity levels at an individual clinic level annually since 1997; The Society for Assisted Reproductive Technology (SART) an organization of ART providers affiliated with the American Society for Reproductive Medicine (ASRM) has been collecting data and publishing annual reports of pregnancy success rates for fertility clinics in the United States and Canada since 1989; In 2017 of all the ART clinics reporting data to CDC 82% were SART members. Population comparison data was obtained from the 1999 to 2018 US Natality files (Birth Cohort dataset) compiled annually by the CDCs National Center for Health Statistics (NCHS); The NCHS provides information on 99% of all registered births each year in the United States"
